WO2007133355A2 - Bone cement compositions comprising an indicator agent and related methods thereof - Google Patents
Bone cement compositions comprising an indicator agent and related methods thereof Download PDFInfo
- Publication number
- WO2007133355A2 WO2007133355A2 PCT/US2007/008789 US2007008789W WO2007133355A2 WO 2007133355 A2 WO2007133355 A2 WO 2007133355A2 US 2007008789 W US2007008789 W US 2007008789W WO 2007133355 A2 WO2007133355 A2 WO 2007133355A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bone cement
- cement
- composition
- color
- bone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- Bone Cement Compositions Comprising an Indicator Agent and Related Methods Thereof
- Bone cements with a specific range or threshold level of viscosity for placement into a cavity within a patient's bone.
- Bone cements that are viscous may be particularly suitable for delivery through a plunger system.
- cement delivered in a low viscosity state may cause medical complications. For example, if the viscosity is not sufficiently viscous, the bone cement may leak outside of the bone cavity, potentially leading to contact of external tissue, such as nerve contact, which may cause nerve damage resulting in subsequent paralysis of the patient.
- the invention relates to methods, compositions, kits and systems for determining one or more cement material properties (e.g., viscosity).
- a color change agent is introduced into a bone cement to allow a physician to determine when the cement has reached the desired viscosity for insertion into a patient.
- a color change agent is incorporated into a bone cement to allow a physician to tell when a cement has the desired viscosity for insertion into a patient.
- a patient refers to any animal that could logically use bone cement including but not limited to humans, other primates, domestics pets, livestock, wild game, and any other animal that has bones.
- a physician when a physician is referenced, it should be understood that it could just as easily refer to a veterinarian or a clinician or any other person who may make use of the bone cement formulations of the present invention.
- Application time can be crucial for delivery of bone cement into bones such as vertebral bodies, since the appropriate viscosity can prevent leakages when performing bone filling surgical procedures such as Kyphoplasty or Vertebroplasty.
- the determination of the right viscosity of a bone cement polymer during its hardening process may also be important to determine the right time for the insertion of knee, hip, elbow and other prostheses.
- a surgeon determined the optimal viscosity of the polymerizing mass by extruding the material out of a loaded bone filler device (BFD) (for example, during Kyphoplasty) after several given time intervals in order to choose the desired viscosity or dough state for application of the bone cement.
- BFD loaded bone filler device
- thermosensitve dye allows the determination of the viscosity of the material by visualizing a color change, so that a physician or surgeon can empty his/her cement delivery device (e.g. a bone cement delivery cannula, etc.) and apply the bone cement when the color of the bone cement begins to change.
- a physician or surgeon can empty his/her cement delivery device (e.g. a bone cement delivery cannula, etc.) and apply the bone cement when the color of the bone cement begins to change.
- the thermosensitive dye can be added to either a bone cement powder or a bone cement liquid. The bone cement powder and the bone cement liquid are then mixed. The mixing of the bone cement powder and the bone cement liquid leads to a chemical reaction that triggers a color change agent to change colors allowing a surgeon to determine the correct time for application of the paste.
- the color change agent is visibly discernible to a user.
- bone cements that generate an exothermic reaction such as polymethyl methacrylate (PMMA) bone cements may be particularly suitable cements for use with a thermosensitive indicator agent.
- PMMA bone cement has been used in orthopedic surgery for over 40 years and is known to have a relatively large exotherm.
- Other cements are suitable for the present invention as long as a color change agent is added to the cement and the color change agent undergoes a color change with a change in a material (e.g. physical and/or chemical) property of the cement, such as a change in temperature, pH, concentration of a component (like a starting material that is being converted to another material), or some other physical property.
- a material e.g. physical and/or chemical
- an indicator agent for detecting such physical/chemical property changes can be used to indicate the particular material state of the cement.
- PMMA bone cements are provided to the physician as two-phase materials that consist of a liquid methylmethacrylate monomer and a fine pre- polymerized polymethylmethacrylate powder.
- the components are usually packaged separately, and may optionally be mixed together in the operating room in a vacuum- mixing chamber (or alternatively, may be mixed without using a vacuum-mixing chamber) and inserted under pressure (or optionally may be inserted without pressure) into the prepared bone cavity before the polymerization reaction is complete.
- the liquid monomer may contain the promoter or accelerator (to initiate the free-radical reaction to generate PMMA) and a stabilizer (to prolong shelf-life) and the powder may contain an initiator (a catalyst) and a radiopacifier.
- Radiopaque material is commonly added to bone cement to enable the radiologist to "see” the cement mantle, monitor its integrity and observe the presence of defects.
- a bone cement maybe made as described in, for example, US Patent No. 6,593,394, which is herein incorporated by reference in its entirety for all purposes.
- a color change agent such as a thermosensitive dye
- the color change can be correlated with another physical change such as a change in viscosity that indicates that a cement has obtained the desired viscosity that is ready to insert into a bone.
- a “color change agent” as referred to in the instant invention refers to an agent that is added to a composition for the purpose of changing color when a physical and/or chemical property of the composition changes.
- a “color change agent” should be distinguished from components in a composition that are not added for the purpose of changing color even if the composition may change color upon a physical change.
- a bone cement that does not have a “color change agent” added to it may as a result of the bone cement undergoing a physical change (such as, for example, a change in viscosity) undergo a slight color change.
- the component(s) that cause this color change are not “color change agents” unless they are added for the express purpose of undergoing the color change to serve as a visual indicator.
- the bone cement according to the present invention may be supplied in a powder-liquid phase (comprising a powder phase and a liquid phase).
- the powder phase material may include surface-treated Sr-HA powder and fumed silica, and a polymerization initiator, whereas the liquid phase may include resins and a polymerization accelerator.
- the powder and liquid phase may contain the color change agent, such as a thermosensitive dye. The surgeon or physician mixes the powder phase material with the liquid phase material, which starts the polymerization process.
- the color change agent such as a thermosensitive dye
- the color change agent will undergo a chemical change leading to a change in chemical structure and a corresponding change in light absorption (i.e., color).
- thermochromic dyes dyes that change color due to a change in temperature
- Thermochromic dyes may be based on mixtures of leucodyes with suitable other chemicals, which display a color change (usually between a colorless leuco form and the colored form of the dye) dependent on the temperature.
- the dyes can be applied on the bone cement directly.
- the dyes can be in the form of microcapsules with a mixture sealed inside.
- An illustrative example is a microcapsule that contains crystal violet lactone, a weak acid, and a dissociable salt dissolved in a nonpolar or slightly polar solvent liquid crystal solvent such as dodecanol or another suitable liquid crystal solvent.
- the dye When the mixture is a solid, the dye exists in its lactone leuco form. However, when the liquid crystal solvent melts, the salt dissociates, the pH inside the microcapsule lowers (making protons readily available), the dye becomes protonated, and the lactone ring opens causing its absorption spectrum to shift, absorbing in the visible spectrum, such as a deeply violet color for crystal violet lactone. Please see the mechanism in Scheme 1 for an example of how a color change may occur in a given compound.
- the non-planar crystal violet lactone compound is colorless but upon protonation of the lactone ring, the lactone ring opens generating a substantially planar conjugated pi system satisfying the H ⁇ ckel rules of aromaticity resulting in a dye that is highly colored (i.e., a dye that absorbs in the visible part of the spectrum).
- a dye that is highly colored i.e., a dye that absorbs in the visible part of the spectrum.
- the temperature change of the dye system shown in scheme 1 is the initiator that causes the crystal violet lactone to undergo a change from colorless to colored, it should be understood that the opposite reaction is contemplated and within the scope of the invention (going from colored to colorless).
- the reverse reaction or a comparable reaction would lead to a change from a colored product to a product that is not colored.
- the reaction in scheme 1 might also be considered a halochromic reaction (a color change caused by a change in pH).
- thermosensitive dye in one embodiment, spirolactones (as shown in Scheme 1) can be used as the thermosensitive dye. It is contemplated and therefore within the scope of the invention that other thermosensitive dyes can be used, such as fluorans, spiropyrans, and fulgides.
- Weak acids that can be used as proton donors include bisphenol A, parabens, 1,2,3-triazole derivatives, and 4-hydroxycoumarin. These weak acids are the proton donor that changes the dye molecule between its leuco form and its protonated colored form. Stronger Bronsted acids (better proton donors) can also be used but they tend to make the color change irreversible.
- thermosensitive dyes are not particularly limited, but it is desired that dyes that are not toxic are used.
- a plurality of thermosensitive dyes are available that change colors at a variety of temperatures. Suitable commercially available the ⁇ nochromic dyes are known which activate at temperatures in the range of 21 to 51° C. These dyes include 744020TC (thermochromic blue), 74401 OTC (thermochromic turquoise), 744027TC (thermochromic yellow), 734010TC(the ⁇ nochromic rose), 724010TC (the ⁇ nochromic orange), 754027TC (thermochromic green) all sold by SICPA Securink Corp. of Springfield, Va. There are also thermochromic dyes which lose color when heated, i.e., change from a color to clear.
- dyes include the compounds 178002TC (Black/clear) from SICPA Securink Corp., which is active at 27 to 36° C.
- Compounds from SICPA Securink Corp. which are active at 22-31° C include: 128001TC (orange/clear),
- Compounds from SICPA Securink Corp. which are active from 24-33° C include: 118000TC (yellow/clear),. 128002TC (orange/clear), 138103TC (vermillion/clear), 15002TC (green/clear), 14001TC (blue/clear), 14000TCBR (blue/red) and 128001TCY (orange/yellow).
- Compounds from SICPA Securink Corp. which are active from 24-33° C include: 118000TC (yellow/clear),. 128002TC (orange/clear), 138103TC (vermillion/clear), 15002TC (green/clear), 14001TC (blue/clear), 14000TCBR (blue/red) and 128001TCY (orange/yellow).
- the dye to be used is not particularly limited as long as it undergoes a change in color with a change in a physical property of the bone cement. Moreover, because the bone cement is to be used in a body, it is desired that the color change agent be not particularly toxic. Preferably, the color change agent is biocompatible.
- color change agents that may be used include indicators that may change color hues with a change in pH, such as a series of indicators that are natural products, such as a natural product from a cabbage. Because the cement is to be used in a patient, it is generally desired that if an indicator is to be used, that it's biological toxicity be limited.
- thermosensitive dye there are a plurality of means of limiting the reaction temperature when making the bone cement, including adding compounds that are known to reduce the temperature, or alternatively, by irrigation with a cool, physiological saline solution or by other means such as reducing the size of cement mantles (for example to 2- 4 mm).
- adding compounds that are known to reduce the temperature or alternatively, by irrigation with a cool, physiological saline solution or by other means such as reducing the size of cement mantles (for example to 2- 4 mm).
- the color change can be detected by visually inspecting the color change.
- a spectrophotometer or some other optical sensor instrument can be used to detect the color change.
- Using an optical sensor is advantageous in that a precise time can be determined as to when the cement has obtained the optimal viscosity whereas visually inspecting the color change is advantageous in that it is less expensive as the optical sensor instrument is not needed.
- using an instrument that can detect color change allows one to find the optimal viscosity when tints of various colors are detected (i.e., small changes on the pantone scale). Generally, the color change of the entire mix will determine when the cement has obtained the optimal viscosity for use.
- PMMA bone cement can be used with 0.1-2 parts or 0.2-0.4 parts of thermosensitive dye.
- the bone cement can be made with, any one or more of the following components: PMMA (or alternatively any of a number of co-polymers can be used, such as methyl methacrylate-styrene copolymer, urethane acrylates, PEG-mono/di-acrylates/methacrylates, epoxidresins, bisphenol-A- glycidyldimethacrylate/triethylene-glycoldimethacrylate formulations), benzoyl peroxide, barium sulfate or zirconium dioxide, N,N-dimethyl toluidine, hydroquinone, ascorbic acid, ethanol, and thermosensitive dye.
- PMMA or alternatively any of a number of co-polymers can be used, such as methyl methacrylate-styrene copolymer, urethane acrylates, PEG-mono/d
- the bone cement may be made with 80-90% PMMA (or alternatively any of a number of co-polymers can be used, such as methyl methacrylate-styrene copolymer), 1-3% benzoyl peroxide, 8-14% barium sulfate or zirconium dioxide, 0.2-1.0% N,N-dimethyl toluidine, 0.01-0.1% hydroquinone, 0.01- 0.1% ascorbic acid, 0.5-1.5% ethanol, and 0.1-0.4% thermosensitive dye and other components such as antibiotics, anticancer agents, and/or re-enforcing materials and the like.
- PMMA polymethyl methacrylate-styrene copolymer
- benzoyl peroxide 8-14% barium sulfate or zirconium dioxide
- 0.2-1.0% N,N-dimethyl toluidine 0.01-0.1% hydroquinone
- 0.01- 0.1% ascorbic acid 0.5-1.5% ethanol
- 10 grams of PMMA bone cement is used with 0.3 grams of a blue thermo sensitive dye that is in a packaging material polymer (such as polypropylene, polystyrol, polyethylene terephthalate, and other similar polymers).
- the PMMA bone cement is made of a liquid component and a powder component.
- the thermo sensitive dye in a packaging material polymer is associated with the powder component.
- an exothermic reaction takes place Upon mixing the liquid component and the powder component (containing the thermosensitive dye) an exothermic reaction takes place.
- the exothermic reaction reaches a temperature at which the thermosensitive dye undergoes a reaction that causes the dye to go from a bluish tint to a less bluish tint to colorless.
- the time at which the dye first starts to change color is when the bone cement has the optimal viscosity for applying the bone cement to a bone.
- the bone cement can be mixed in a plunger (or syringe) or alternatively, in a reaction flask (and then loaded into a device for applying the bone cement). If the mixing occurs in a plunger (or syringe) it is desirable for the plunger (or syringe) to be transparent so that the changing color is readily observable.
- the bone cement may contain additional components.
- additional components include one or more antibiotics such as gentamicin, gentamicin sulfate, erythromycin, tobramycin, vancomycin, cefazolin, oxacillin, cefotaxime, colistin, clindamycin, and/or fusidic acid.
- antibiotics such as gentamicin, gentamicin sulfate, erythromycin, tobramycin, vancomycin, cefazolin, oxacillin, cefotaxime, colistin, clindamycin, and/or fusidic acid.
- the antibiotic or antibiotics that are used are stable or at least somewhat stable under heat conditions or under conditions wherein the antibiotic can tolerate some change in physical conditions such as a change in the pH. This is because the color change in the bone cement occurs because of a change in physical condition.
- gentamicin sulfate is a suitable antibiotic for the present invention is because it is wide spectrum antibiotic that
- additional components that can be added to the bone cement of the present invention include one or more radiopacifxer compounds such as barium sulfate, 2-[2',3',5'-triiodobenzoyl] ethyl methacrylate (TIBMA), 3,5-diiodine salicylic methacrylate (DISMA), and/or zirconium(IV) oxide. It is contemplated that other compounds that can be seen under fluoroscopic guidance can be used as radiopacifier compounds. Additionally, anticancer agents can be added to the bone cement such as 6- mercaptopurine, methotrexate and/or cisplatin.
- radiopacifxer compounds such as barium sulfate, 2-[2',3',5'-triiodobenzoyl] ethyl methacrylate (TIBMA), 3,5-diiodine salicylic methacrylate (DISMA), and/or zirconium(IV) oxide. It is contemplated that other
- re-enforcing materials such as hydroxy apatite (HA) powder, K 2 O-Na 2 -CaO-MgO-SiO 2 -P 2 O 5 crystallized glass powder, calcium phosphate, carbon, graphite, aramid, bone particle, polyethylene, titanium, ultra high weight polyethylene, polymethylmethacrylate fibers in a cement matrix, tricalcium phosphate, and hydroxycarbonate apatite, and the like.
- HA hydroxy apatite
- K 2 O-Na 2 -CaO-MgO-SiO 2 -P 2 O 5 crystallized glass powder such as calcium phosphate, carbon, graphite, aramid, bone particle, polyethylene, titanium, ultra high weight polyethylene, polymethylmethacrylate fibers in a cement matrix, tricalcium phosphate, and hydroxycarbonate apatite, and the like.
- the present invention is directed to a composition comprising a curable bioactive agent and a color change agent.
- the present invention is directed to a composition comprising a bone cement and a color change agent.
- the color change agent of the present invention in one embodiment is a thermosensitive dye.
- One or more leucodyes are suitable as thermo sensitive dyes that can be used in the present invention. Any change in color from a color to colorless or from colorless to a color is contemplated. An example of a contemplated color change is from blue to colorless or from colorless to blue. Other color changes include whitish/grayish to bluish, whitish to redish, or any color change that has a color change agent available that will change from one color hue to another color hue based on a physical or chemical property changing.
- Bone cements that undergo a change in a physical property such as polymethyl methacrylate polymer cements are suitable for the present invention.
- the bone cement generally is comprised of a bone cement powder and/or a bone cement liquid, which is generally made by mixing together the bone cement powder with the bone cement liquid.
- the antibiotic, the radiopacifier compound, the anticancer agent, or the re- enforcing material is selected from one or members from the group consisting of gentamicin sulfate, erythromycin, tobramycin, vancomycin, cefazolin, oxacillin, cefotaxime, colistin, clindamycin, fusidic acid, barium sulfate, zirconium(IV) oxide, methotrexate, cisplatin, carbon, graphite, aramid, bone particle, polyethylene, titanium, ultra high weight polyethylene, polymethylmethacrylate fibers in a cement matrix, tricalcium phosphate, and hydroxycarbonate apatite.
- the present invention relates to a method of preparing a bone cement containing a color change agent wherein the method comprises: mixing together a powder and liquid phase to generate a bone cement, wherein either or both of the powder or liquid phase contain the color change agent.
- the present invention is directed to a kit having a first material and a second material, wherein when at least the first material and the second material are mixed together a bone cement is generated.
- the kit optionally also contains a color chart including at least one colored area, wherein the colored area contains a reference color for determining whether the bone cement has achieved a given material property after the first material and second material are mixed.
- the kit also contains written instructions instructing a user how to determine when the bone cement has attained a given material property.
- the material property may be a predefined viscosity state of the bone cement, or alternatively, a predefined temperature threshold.
- the first material is a powder and the second material is a liquid.
- the instant invention relates to a system having a first material and a second material, a mixer for mixing at least the first material and the second material to form a bone cement; and an indicator agent configured to provide an indication of a material property of the bone cement during mixing or after mixing the first material and the second material in the mixer.
- the indicator agent may be configured to provide a visual indication when the property of the bone cement has reached a material characteristic threshold.
- the material characteristic threshold is a predefined viscosity or alternatively, a predefined temperature threshold.
- the system of the present invention further optionally may contain written instructions associated with the system. Example
- the following composition is mixed together: powder 1O g PMMA MW 422 with 2.2% BPO (benzoyl peroxide) (50%) + 3 g BaSO 4
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007250161A AU2007250161A1 (en) | 2006-05-02 | 2007-04-11 | Bone cement compositions comprising an indicator agent and related methods thereof |
JP2009509576A JP2009535153A (en) | 2006-05-02 | 2007-04-11 | Bone cement composition containing an indicator and methods related thereto |
CN200780018562.7A CN101511396B (en) | 2006-05-02 | 2007-04-11 | Bone cement compositions comprising an indicator agent and related methods thereof |
EP07775048A EP2019694A2 (en) | 2006-05-02 | 2007-04-11 | Bone cement compositions comprising an indicator agent and related methods thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/416,093 US7754005B2 (en) | 2006-05-02 | 2006-05-02 | Bone cement compositions comprising an indicator agent and related methods thereof |
US11/416,093 | 2006-05-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007133355A2 true WO2007133355A2 (en) | 2007-11-22 |
WO2007133355A3 WO2007133355A3 (en) | 2008-10-09 |
Family
ID=38654765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/008789 WO2007133355A2 (en) | 2006-05-02 | 2007-04-11 | Bone cement compositions comprising an indicator agent and related methods thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US7754005B2 (en) |
EP (1) | EP2019694A2 (en) |
JP (1) | JP2009535153A (en) |
KR (1) | KR20090017556A (en) |
CN (1) | CN101511396B (en) |
AU (1) | AU2007250161A1 (en) |
WO (1) | WO2007133355A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010112955A1 (en) * | 2009-03-30 | 2010-10-07 | Vexim | Bone cement kit and related methods of use |
EP2497504A2 (en) * | 2009-11-06 | 2012-09-12 | Injecta Inc. | Paste-powder dual polymer-based bone cement and injection apparatus for same |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090259263A1 (en) * | 2008-04-11 | 2009-10-15 | Biomet Microfixation, Inc. | Apparatus and methods of fixating bone |
WO2009143236A1 (en) * | 2008-05-20 | 2009-11-26 | Albert Einstein Healthcare Network | Compositions and methods for the treatment of skeletal metastatic lesions and fractures |
US9492375B2 (en) | 2008-07-23 | 2016-11-15 | Warsaw Orthopedic, Inc. | Foam carrier for bone grafting |
US8133436B2 (en) * | 2008-08-05 | 2012-03-13 | Howmedica Osteonics Corp. | Polyethylene cross-linked with an anthocyanin |
DE102009031261A1 (en) * | 2009-06-30 | 2011-03-10 | Karl Storz Gmbh & Co. Kg | Method and solder for integrally joining two surfaces |
IT1394800B1 (en) * | 2009-07-10 | 2012-07-13 | Univ Degli Studi Torino | BONE COMPOSITE CEMENTS WITH PMMA MATRIX, CONTAINING BIOACTIVE AND ANTIBACTERIAL GLASSES AND CERAMIC GLASSES |
EP2512537B1 (en) * | 2009-12-18 | 2015-08-26 | Howmedica Osteonics Corp. | Dual paste direct injectable bone cement precursor systems and methods of making same |
CA2789793C (en) * | 2010-03-05 | 2019-01-15 | Synthes Usa, Llc | Bone cement system for bone augmentation |
DE102010024653B4 (en) * | 2010-06-22 | 2012-06-21 | Heraeus Medical Gmbh | Kit for making bone cement and using this kit |
ES2714701T3 (en) | 2010-11-10 | 2019-05-29 | Stryker European Holdings I Llc | Process for the preparation of a polymeric bone foam |
DE102012014418A1 (en) * | 2012-07-20 | 2014-01-23 | Heraeus Medical Gmbh | Pasty bone cement |
EP3257109B1 (en) * | 2015-02-11 | 2022-06-22 | Alpha Assembly Solutions Inc. | Electrical connection tape |
US9925363B2 (en) * | 2015-02-16 | 2018-03-27 | Augusto Magagnoli | Spacer device for treatment of an infected seat of the human body |
CN108992706A (en) * | 2018-08-08 | 2018-12-14 | 上海应用技术大学 | A kind of antibiotic continues acrylic resin bone cement efficiently discharged and preparation method thereof |
CN109010909A (en) * | 2018-09-05 | 2018-12-18 | 杭州市萧山区中医院 | The compound erythromycin bone cement of polymethyl methacrylate is used to prevent and treat the application of Periprosthetic bone dissolution and inflammatory reaction |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030139488A1 (en) * | 2002-01-18 | 2003-07-24 | Loctite Corporation | (Meth) Acrylate compositions having a self-indicator of cure and methods of detecting cure |
FR2838334A1 (en) * | 2002-04-16 | 2003-10-17 | Polymerexpert Sa | Use of tertiary amines as activators for the decomposition of radical initiators, especially in bone cement and dental cement compositions |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US695359A (en) * | 1901-09-21 | 1902-03-11 | Philip W Wolfe | Scoop. |
US3746680A (en) | 1971-03-03 | 1973-07-17 | Johnson & Johnson | Plaster of paris composition |
DE2320373B2 (en) * | 1973-04-21 | 1978-04-06 | Merck Patent Gmbh, 6100 Darmstadt | Antibiotic agent and its use as a plastic surgical material |
US4141864A (en) | 1974-03-15 | 1979-02-27 | University Of Virginia Alumni Patents Foundation | Osseous cement composition |
AT352867B (en) | 1976-05-12 | 1979-10-10 | Battelle Institut E V | BONE REPLACEMENT, BONE COMPOUND OR PROSTHESIS ANCHORING MATERIAL AND PROCESS FOR ITS PRODUCTION |
DE2724814C3 (en) * | 1977-06-02 | 1980-03-27 | Kulzer & Co Gmbh, 6380 Bad Homburg | Preliminary product for the preparation of bone cement |
US4404327A (en) | 1979-10-31 | 1983-09-13 | Crugnola Aldo M | Orthopaedic cement from acrylate polymers |
US4341691A (en) | 1980-02-20 | 1982-07-27 | Zimmer, Inc. | Low viscosity bone cement |
US4518430A (en) | 1982-04-29 | 1985-05-21 | American Dental Association Health Foundation | Dental resptorative cement pastes |
DE3245956A1 (en) | 1982-12-11 | 1984-06-14 | Beiersdorf Ag, 2000 Hamburg | SURGICAL MATERIAL |
US4612053A (en) | 1983-10-06 | 1986-09-16 | American Dental Association Health Foundation | Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements |
US4722948A (en) | 1984-03-16 | 1988-02-02 | Dynatech Corporation | Bone replacement and repair putty material from unsaturated polyester resin and vinyl pyrrolidone |
US4629464A (en) | 1984-09-25 | 1986-12-16 | Tdk Corporation | Porous hydroxyapatite material for artificial bone substitute |
JPS61271203A (en) * | 1985-05-27 | 1986-12-01 | G C Dental Ind Corp | Dental discoloring cement composition |
GB8524152D0 (en) | 1985-10-01 | 1985-11-06 | Cole Polymers Ltd | Bone cement |
DE3536076A1 (en) | 1985-10-09 | 1987-04-09 | Muehlbauer Ernst Kg | POLYMERIZABLE CEMENT MIXTURES |
JPS62182146A (en) | 1985-10-11 | 1987-08-10 | 三井東圧化学株式会社 | Hardenable material |
GB2197329B (en) | 1986-09-10 | 1990-01-10 | Showa Denko Kk | Hard tissue substitute composition |
JPS63305188A (en) | 1987-06-06 | 1988-12-13 | Sony Corp | Display material |
JPS6433536A (en) | 1987-07-29 | 1989-02-03 | Sony Corp | Electrochromic display device |
US4837279A (en) * | 1988-02-22 | 1989-06-06 | Pfizer Hospital Products Corp, Inc. | Bone cement |
JPH01230413A (en) | 1988-03-11 | 1989-09-13 | Kanto Chem Co Inc | Production of spherical hydroxyapatite sintered form and chromatographic filler consisting thereof |
US5205928A (en) | 1988-03-11 | 1993-04-27 | Kanto Kagaku Kabushiki Kaisha | Process for the preparation of microspherical sintered bodies of hydroxyapatite and a chromatographic packing material comprising the microspherical sintered bodies of hydroxyapatite |
US6002065A (en) | 1988-04-20 | 1999-12-14 | Norian Corporation | Kits for preparing calcium phosphate minerals |
US5962028A (en) | 1988-04-20 | 1999-10-05 | Norian Corporation | Carbonated hydroxyapatite compositions and uses |
IT1234978B (en) | 1988-06-01 | 1992-06-09 | Tecres Spa | TWO-STAGE CEMENTITIOUS MIXTURE, PARTICULARLY SUITABLE FOR ORTHOPEDIC USES. |
DE68911811T2 (en) | 1988-09-20 | 1994-06-09 | Asahi Optical Co Ltd | Porous ceramic sinter and process for its production. |
US5179065A (en) | 1989-04-28 | 1993-01-12 | Sony Corporation | Recording material with a display composition including a coloring pigment |
JP2770409B2 (en) | 1989-04-28 | 1998-07-02 | ソニー株式会社 | Display composition, coloring pigment and recording material |
US5226877A (en) | 1989-06-23 | 1993-07-13 | Epstein Gordon H | Method and apparatus for preparing fibrinogen adhesive from whole blood |
EP0439250B1 (en) | 1990-01-25 | 1994-11-02 | Howmedica Inc. | Bone cement |
JPH042372U (en) * | 1990-04-23 | 1992-01-09 | ||
EP0542794B1 (en) | 1990-07-27 | 1995-12-13 | Exxon Chemical Patents Inc. | Hydrocarbon treatment |
EP0473048B1 (en) | 1990-08-21 | 1996-11-27 | Asahi Glass Company Ltd. | Calcium phosphate type glass-ceramic |
US5149368A (en) | 1991-01-10 | 1992-09-22 | Liu Sung Tsuen | Resorbable bioactive calcium phosphate cement |
US5462722A (en) | 1991-04-17 | 1995-10-31 | Liu; Sung-Tsuen | Calcium phosphate calcium sulfate composite implant material |
US5262166A (en) | 1991-04-17 | 1993-11-16 | Lty Medical Inc | Resorbable bioactive phosphate containing cements |
EP0511868B1 (en) | 1991-05-01 | 1996-09-25 | Chichibu Onoda Cement Corporation | Medical or dental hardening compositions |
EP0520690B1 (en) | 1991-06-26 | 1995-11-02 | Nitta Gelatin Inc. | Calcium phosphate type hardening material for repairing living hard tissue |
US5605713A (en) | 1991-11-22 | 1997-02-25 | Boltong; Maria G. | Process for the preparation of calcium phosphate cements and its application as bio-materials |
ES2040626B1 (en) | 1991-11-22 | 1994-05-16 | Boltong Maria G | PROCEDURE FOR THE OBTAINING OF CALCIUM PHOSPHATE CEMENTS AND THEIR USE AS BIOMTERIALS. |
US5281265A (en) | 1992-02-03 | 1994-01-25 | Liu Sung Tsuen | Resorbable surgical cements |
US5204382A (en) | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
ATE269371T1 (en) | 1992-02-28 | 2004-07-15 | Cohesion Tech Inc | INJECTABLE CERAMIC COMPOUNDS AND METHOD FOR THEIR PRODUCTION AND USE |
US5522893A (en) | 1993-03-12 | 1996-06-04 | American Dental Association Health Foundation | Calcium phosphate hydroxyapatite precursor and methods for making and using the same |
US6248110B1 (en) | 1994-01-26 | 2001-06-19 | Kyphon, Inc. | Systems and methods for treating fractured or diseased bone using expandable bodies |
US6241734B1 (en) | 1998-08-14 | 2001-06-05 | Kyphon, Inc. | Systems and methods for placing materials into bone |
US5462356A (en) | 1994-06-01 | 1995-10-31 | Murray; William M. | Bone and dental cement method and preform |
US6075067A (en) | 1994-08-15 | 2000-06-13 | Corpipharm Gmbh & Co | Cement for medical use, method for producing the cement, and use of the cement |
DE4433201A1 (en) | 1994-09-17 | 1996-03-21 | Merck Patent Gmbh | Process for the production of active ingredient-containing bone cements |
DE4435680A1 (en) | 1994-10-06 | 1996-04-11 | Merck Patent Gmbh | Porous bone substitute materials |
US5569442A (en) | 1994-11-04 | 1996-10-29 | Norian Corporation | Reactive tricalcium phosphate compositions and uses |
GB0102529D0 (en) | 2001-01-31 | 2001-03-21 | Thales Optronics Staines Ltd | Improvements relating to thermal imaging cameras |
US5795922A (en) | 1995-06-06 | 1998-08-18 | Clemson University | Bone cement composistion containing microencapsulated radiopacifier and method of making same |
US5814683A (en) * | 1995-12-06 | 1998-09-29 | Hewlett-Packard Company | Polymeric additives for the elimination of ink jet aerosol generation |
DE29607832U1 (en) * | 1996-04-30 | 1996-10-24 | Huebner Eike Gerhard | Indicator for the hardening of bone cement |
US6953594B2 (en) | 1996-10-10 | 2005-10-11 | Etex Corporation | Method of preparing a poorly crystalline calcium phosphate and methods of its use |
US5914356A (en) | 1996-12-06 | 1999-06-22 | Orthovita, Inc. | Bioactive load bearing bone bonding compositions |
US5847046A (en) | 1997-03-12 | 1998-12-08 | United States Surgical Corporation | Biodegradable bone cement |
JP3679570B2 (en) | 1997-03-14 | 2005-08-03 | ペンタックス株式会社 | Bone prosthetic material and manufacturing method thereof |
US6071982A (en) | 1997-04-18 | 2000-06-06 | Cambridge Scientific, Inc. | Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same |
US6309420B1 (en) | 1997-10-14 | 2001-10-30 | Parallax Medical, Inc. | Enhanced visibility materials for implantation in hard tissue |
FR2772746B1 (en) | 1997-12-23 | 2000-01-28 | Commissariat Energie Atomique | PROCESS FOR THE MANUFACTURE OF AN APATITIC CERAMIC, PARTICULARLY FOR BIOLOGICAL USE |
FR2776282B1 (en) | 1998-03-20 | 2000-05-19 | Toulouse Inst Nat Polytech | PROCESS FOR THE PREPARATION OF A HYDROXYAPATITE-BASED BIOMATERIAL, BIOMATERIAL OBTAINED AND SURGICAL OR DENTAL APPLICATION |
CA2327730A1 (en) | 1998-04-10 | 1999-10-21 | Wm Marsh Rice University | Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger |
JP3360810B2 (en) | 1998-04-14 | 2003-01-07 | ペンタックス株式会社 | Method for producing bone replacement material |
DE19816858A1 (en) | 1998-04-16 | 1999-10-21 | Merck Patent Gmbh | Tricalcium phosphate-containing bio-cement pastes with cohesion promoters |
US6224635B1 (en) | 1998-11-06 | 2001-05-01 | Hospital For Joint Diseases | Implantation of surgical implants with calcium sulfate |
DE19853832A1 (en) | 1998-11-21 | 2000-05-25 | Merck Patent Gmbh | Calcium phosphate cements containing polyalkenoic acids |
FR2786899B1 (en) * | 1998-12-03 | 2006-09-29 | Jean Bonnard | MOVEMENT INDICATOR FOR SOFTWARE |
US6436143B1 (en) | 1999-02-22 | 2002-08-20 | Anthony C. Ross | Method and apparatus for treating intervertebral disks |
CA2287112C (en) | 1999-09-02 | 2008-02-19 | Kieran Murphy | Method and apparatus for strengthening vertebral bodies |
JP4498501B2 (en) * | 1999-10-20 | 2010-07-07 | 株式会社ジーシー | Dental glass ionomer cement composition |
US6593394B1 (en) | 2000-01-03 | 2003-07-15 | Prosperous Kingdom Limited | Bioactive and osteoporotic bone cement |
AU2001231264A1 (en) | 2000-01-31 | 2001-08-07 | Advanced Research And Technology Institute, Inc. | Composite biomaterial including anisometric calcium phosphate reinforcement particles and related methods |
SE520688C2 (en) | 2000-04-11 | 2003-08-12 | Bone Support Ab | An injectable bone mineral replacement material |
DE10032220A1 (en) | 2000-07-03 | 2002-01-24 | Sanatis Gmbh | Magnesium ammonium phosphate cements, their manufacture and use |
SE517168C2 (en) | 2000-07-17 | 2002-04-23 | Bone Support Ab | A composition for an injectable bone mineral replacement material |
US6808561B2 (en) | 2000-10-16 | 2004-10-26 | University Of South Carolina | Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement |
EP1333912A2 (en) | 2000-10-25 | 2003-08-13 | Kyphon Inc. | Systems and methods for mixing and transferring flowable materials |
US6547866B1 (en) | 2000-10-30 | 2003-04-15 | Howmedica Osteonics Corp. | Porous calcium phosphate cement |
US6562755B1 (en) | 2000-10-31 | 2003-05-13 | Ncr Corporation | Thermal paper with security features |
US6497901B1 (en) | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
DE10106372A1 (en) * | 2001-02-12 | 2002-08-29 | Ivoclar Vivadent Ag | Thermochromic dental material |
US7008433B2 (en) | 2001-02-15 | 2006-03-07 | Depuy Acromed, Inc. | Vertebroplasty injection device |
US20070191964A1 (en) | 2001-04-04 | 2007-08-16 | Arthrocare Corporation | Enhanced visibility materials for implantation in hard tissue |
US20040265385A1 (en) | 2001-04-12 | 2004-12-30 | Therics, Inc. | Porous biostructure partially occupied by interpenetrant and method for making same |
EP1388024A1 (en) | 2001-04-25 | 2004-02-11 | Koninklijke Philips Electronics N.V. | Electrophoretic color display device |
US20030055512A1 (en) | 2001-05-21 | 2003-03-20 | Genin Francois Y. | Calcium based neutral and bioresorbable bone graft |
ITVI20010126A1 (en) | 2001-05-30 | 2002-11-30 | Tecres Spa | RADIOPACO BONE CEMENT FOR ORTHOPEDIC USE AND METHOD OF REALIZATION |
TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
EP1499267A4 (en) | 2002-02-05 | 2008-10-29 | Depuy Mitek Inc | Bioresorbable osteoconductive compositions for bone regeneration |
DE10225420A1 (en) | 2002-06-07 | 2003-12-24 | Sanatis Gmbh | Strontium apatite cement preparations, the cements formed therefrom and the use thereof |
US7273523B2 (en) | 2002-06-07 | 2007-09-25 | Kyphon Inc. | Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof |
US7138442B2 (en) | 2002-08-30 | 2006-11-21 | Biomet, Inc. | Reduced exothermic bone replacement cement |
DE10242984B4 (en) | 2002-09-17 | 2010-09-23 | Sanatis Gmbh | Device for producing mixtures of two components |
US7135027B2 (en) | 2002-10-04 | 2006-11-14 | Baxter International, Inc. | Devices and methods for mixing and extruding medically useful compositions |
DE20218668U1 (en) | 2002-12-03 | 2003-03-06 | Sanatis Gmbh | Recipes for cement preparations as a bone substitute |
DE10340800A1 (en) | 2002-12-20 | 2004-07-01 | Merck Patent Gmbh | Production of acrylic bone cement, e.g. for anchoring prostheses in bone, involves using X-ray contrast medium which has been functionalised with (meth)acrylate after coating with melamine-formaldehyde resin |
US20070032567A1 (en) | 2003-06-17 | 2007-02-08 | Disc-O-Tech Medical | Bone Cement And Methods Of Use Thereof |
WO2006011152A2 (en) | 2004-06-17 | 2006-02-02 | Disc-O-Tech Medical Technologies, Ltd. | Methods for treating bone and other tissue |
DE112004001799D2 (en) | 2003-07-18 | 2006-07-06 | Biomet Deutschland Gmbh | Surfactant-containing bone cement |
US6994726B2 (en) | 2004-05-25 | 2006-02-07 | Calcitec, Inc. | Dual function prosthetic bone implant and method for preparing the same |
US20050105384A1 (en) | 2003-11-18 | 2005-05-19 | Scimed Life Systems, Inc. | Apparatus for mixing and dispensing a multi-component bone cement |
DE10355992A1 (en) | 2003-11-27 | 2005-06-30 | Curasan Ag | Bioresorbable composite material |
US7351280B2 (en) | 2004-02-10 | 2008-04-01 | New York University | Macroporous, resorbable and injectible calcium phosphate-based cements (MCPC) for bone repair, augmentation, regeneration, and osteoporosis treatment |
FR2870129A1 (en) | 2004-05-14 | 2005-11-18 | Ceravic Sas Soc Par Actions Si | POLYMERIC CEMENT FOR PERCUTANEOUS VERTEBROPLASTY |
DE102005032110B3 (en) * | 2005-07-07 | 2006-08-17 | Heraeus Kulzer Gmbh | Colored polymethyl-methacrylate cement to anchor endoprostheses in orthopoedic surgery incorporates a mixture of one or more dyes |
US20070021526A1 (en) * | 2005-07-22 | 2007-01-25 | Howmedica Osteonics Corp. | Setting time indicator for acrylic bone cement |
US7651701B2 (en) | 2005-08-29 | 2010-01-26 | Sanatis Gmbh | Bone cement composition and method of making the same |
US8147860B2 (en) | 2005-12-06 | 2012-04-03 | Etex Corporation | Porous calcium phosphate bone material |
-
2006
- 2006-05-02 US US11/416,093 patent/US7754005B2/en active Active
-
2007
- 2007-04-11 EP EP07775048A patent/EP2019694A2/en not_active Withdrawn
- 2007-04-11 JP JP2009509576A patent/JP2009535153A/en active Pending
- 2007-04-11 AU AU2007250161A patent/AU2007250161A1/en not_active Abandoned
- 2007-04-11 CN CN200780018562.7A patent/CN101511396B/en not_active Expired - Fee Related
- 2007-04-11 KR KR1020087029342A patent/KR20090017556A/en not_active Application Discontinuation
- 2007-04-11 WO PCT/US2007/008789 patent/WO2007133355A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030139488A1 (en) * | 2002-01-18 | 2003-07-24 | Loctite Corporation | (Meth) Acrylate compositions having a self-indicator of cure and methods of detecting cure |
FR2838334A1 (en) * | 2002-04-16 | 2003-10-17 | Polymerexpert Sa | Use of tertiary amines as activators for the decomposition of radical initiators, especially in bone cement and dental cement compositions |
Non-Patent Citations (1)
Title |
---|
LEE C L ET AL: "LASER ABLATION OF DYED ACRYLIC BONE CEMENT" LASERS IN SURGERY AND MEDICINE, WILEY- LISS, NEW YORK, US, vol. 20, no. 3, 1 January 1997 (1997-01-01), pages 280-289, XP000694435 ISSN: 0196-8092 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010112955A1 (en) * | 2009-03-30 | 2010-10-07 | Vexim | Bone cement kit and related methods of use |
EP2497504A2 (en) * | 2009-11-06 | 2012-09-12 | Injecta Inc. | Paste-powder dual polymer-based bone cement and injection apparatus for same |
EP2497504A4 (en) * | 2009-11-06 | 2014-06-04 | Injecta Inc | Paste-powder dual polymer-based bone cement and injection apparatus for same |
US10016526B2 (en) | 2009-11-06 | 2018-07-10 | Injecta Inc. | Paste-powder dual polymer-based bone cement and injection apparatus for same |
Also Published As
Publication number | Publication date |
---|---|
US7754005B2 (en) | 2010-07-13 |
KR20090017556A (en) | 2009-02-18 |
AU2007250161A1 (en) | 2007-11-22 |
EP2019694A2 (en) | 2009-02-04 |
WO2007133355A3 (en) | 2008-10-09 |
CN101511396A (en) | 2009-08-19 |
US20070260325A1 (en) | 2007-11-08 |
JP2009535153A (en) | 2009-10-01 |
CN101511396B (en) | 2013-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7754005B2 (en) | Bone cement compositions comprising an indicator agent and related methods thereof | |
Kühn | Bone cements: up-to-date comparison of physical and chemical properties of commercial materials | |
EP2130520B1 (en) | Device for measuring the temperature of bone cement | |
ES2373975T3 (en) | BONE CEMENT AND PROCEDURE FOR USE. | |
Kuehn et al. | Acrylic bone cements: composition and properties | |
CA2395910C (en) | Bioactive and osteoporotic bone cement | |
US20070021526A1 (en) | Setting time indicator for acrylic bone cement | |
US8536243B2 (en) | Two-component system for bone cement | |
US10016526B2 (en) | Paste-powder dual polymer-based bone cement and injection apparatus for same | |
KR101851410B1 (en) | Bone cement system for bone augmentation | |
BRPI0602636B1 (en) | COLORED POLYMETHYMETRYLATE BONE CEMENT AND PROCESS FOR DYING THE POLYMERIC PARTICULES OF THE POLYMETHYMEETRYLATE BONE CEMENT POWDER | |
CN107223060A (en) | Ternary mixture and its implementation for bone cement | |
KR20150140746A (en) | Acrylic cements for bone augmentation | |
Murray et al. | Influence of gamma and electron beam sterilization on the stability of a premixed injectable calcium phosphate cement for trauma indications | |
US20220288272A1 (en) | Implant comprising a plurality of hardening states | |
US8415406B2 (en) | Setting time indicator for acrylic bone cement | |
Bongio et al. | Development of an in vitro confinement test to predict the clinical handling of polymer-based injectable bone substitutes | |
CONTENT | The study aim was development of composite bone cements with lower monomer content, viscosity and modulus but a higher conversion and strength than the commercial composite CortossTM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780018562.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07775048 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007250161 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009509576 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2007250161 Country of ref document: AU Date of ref document: 20070411 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007775048 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087029342 Country of ref document: KR |